Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dependovirus | 14 | 2025 | 695 | 1.950 |
Why?
|
| Genetic Vectors | 11 | 2025 | 851 | 1.450 |
Why?
|
| MicroRNAs | 7 | 2025 | 675 | 1.430 |
Why?
|
| Liver Failure, Acute | 1 | 2025 | 24 | 0.960 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2025 | 53 | 0.920 |
Why?
|
| Acetaminophen | 1 | 2025 | 59 | 0.920 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2024 | 20 | 0.850 |
Why?
|
| Gene Silencing | 3 | 2019 | 392 | 0.800 |
Why?
|
| Genetic Therapy | 10 | 2024 | 771 | 0.780 |
Why?
|
| Genome, Viral | 2 | 2019 | 133 | 0.660 |
Why?
|
| Gene Expression Regulation | 1 | 2025 | 1611 | 0.580 |
Why?
|
| Inverted Repeat Sequences | 1 | 2017 | 14 | 0.550 |
Why?
|
| Osteoporosis | 3 | 2024 | 108 | 0.540 |
Why?
|
| Mice | 18 | 2025 | 10806 | 0.520 |
Why?
|
| DNA, Viral | 1 | 2017 | 231 | 0.510 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 2175 | 0.480 |
Why?
|
| Animals | 22 | 2025 | 20586 | 0.430 |
Why?
|
| Myositis Ossificans | 2 | 2023 | 6 | 0.420 |
Why?
|
| Transgenes | 3 | 2024 | 186 | 0.400 |
Why?
|
| Gene Editing | 3 | 2024 | 310 | 0.370 |
Why?
|
| Liver | 3 | 2025 | 845 | 0.300 |
Why?
|
| Nucleic Acid Conformation | 2 | 2019 | 242 | 0.280 |
Why?
|
| Schistosomiasis | 2 | 2018 | 4 | 0.270 |
Why?
|
| Activin Receptors, Type I | 2 | 2023 | 14 | 0.270 |
Why?
|
| Transduction, Genetic | 2 | 2019 | 236 | 0.260 |
Why?
|
| Macaca mulatta | 2 | 2024 | 248 | 0.260 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2025 | 15 | 0.240 |
Why?
|
| Glutathione Transferase | 1 | 2025 | 41 | 0.240 |
Why?
|
| Capsid | 3 | 2023 | 96 | 0.240 |
Why?
|
| Gene Expression | 2 | 2019 | 837 | 0.230 |
Why?
|
| Alveolar Bone Loss | 1 | 2024 | 5 | 0.230 |
Why?
|
| Humans | 19 | 2025 | 62693 | 0.220 |
Why?
|
| Adenine | 1 | 2024 | 50 | 0.210 |
Why?
|
| CRISPR-Cas Systems | 2 | 2024 | 349 | 0.210 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2024 | 41 | 0.210 |
Why?
|
| Nanopores | 1 | 2022 | 11 | 0.200 |
Why?
|
| Ossification, Heterotopic | 1 | 2022 | 13 | 0.200 |
Why?
|
| Motor Neurons | 1 | 2024 | 212 | 0.200 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 898 | 0.190 |
Why?
|
| Bone and Bones | 2 | 2022 | 142 | 0.190 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 1184 | 0.190 |
Why?
|
| Mitochondrial Myopathies | 1 | 2021 | 4 | 0.190 |
Why?
|
| Thymidine Kinase | 1 | 2021 | 18 | 0.190 |
Why?
|
| Codon, Nonsense | 1 | 2022 | 58 | 0.180 |
Why?
|
| Gene Transfer Techniques | 3 | 2021 | 315 | 0.180 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 207 | 0.180 |
Why?
|
| Fractures, Bone | 1 | 2022 | 142 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 1 | 2024 | 671 | 0.180 |
Why?
|
| Gene Order | 2 | 2019 | 32 | 0.180 |
Why?
|
| Hepatic Stellate Cells | 2 | 2018 | 24 | 0.170 |
Why?
|
| Bone Resorption | 1 | 2019 | 41 | 0.160 |
Why?
|
| Capsid Proteins | 1 | 2020 | 98 | 0.160 |
Why?
|
| Dopaminergic Neurons | 1 | 2019 | 38 | 0.150 |
Why?
|
| Infant | 1 | 2024 | 1605 | 0.150 |
Why?
|
| RNA Stability | 1 | 2019 | 102 | 0.150 |
Why?
|
| Lung | 1 | 2024 | 939 | 0.150 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2019 | 37 | 0.150 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 78 | 0.150 |
Why?
|
| Corpus Striatum | 1 | 2019 | 96 | 0.150 |
Why?
|
| RNA, Untranslated | 1 | 2019 | 102 | 0.150 |
Why?
|
| Cocaine | 1 | 2019 | 101 | 0.150 |
Why?
|
| Schistosoma | 1 | 2018 | 3 | 0.150 |
Why?
|
| RNA, Viral | 1 | 2019 | 272 | 0.150 |
Why?
|
| Interleukin-33 | 1 | 2018 | 18 | 0.150 |
Why?
|
| Mitochondria | 1 | 2021 | 366 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 203 | 0.140 |
Why?
|
| Male | 8 | 2025 | 29494 | 0.140 |
Why?
|
| Sequence Deletion | 1 | 2017 | 117 | 0.130 |
Why?
|
| Genes, Reporter | 1 | 2017 | 256 | 0.130 |
Why?
|
| Plasmids | 1 | 2017 | 292 | 0.130 |
Why?
|
| Cell Line | 2 | 2019 | 2038 | 0.130 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2017 | 87 | 0.130 |
Why?
|
| RNA Interference | 1 | 2019 | 618 | 0.130 |
Why?
|
| Adenoviridae | 3 | 2022 | 121 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 406 | 0.120 |
Why?
|
| Liver Diseases, Parasitic | 1 | 2015 | 4 | 0.120 |
Why?
|
| Interleukin-13 | 1 | 2015 | 37 | 0.120 |
Why?
|
| DNA Replication | 1 | 2017 | 234 | 0.120 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2015 | 60 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 2012 | 29 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2012 | 28 | 0.110 |
Why?
|
| Translocation, Genetic | 2 | 2012 | 68 | 0.110 |
Why?
|
| Receptors, AMPA | 1 | 2013 | 42 | 0.100 |
Why?
|
| Amygdala | 1 | 2013 | 83 | 0.100 |
Why?
|
| Reward | 1 | 2013 | 87 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2012 | 32 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2012 | 28 | 0.090 |
Why?
|
| Osteogenesis | 2 | 2023 | 146 | 0.090 |
Why?
|
| Pyrazines | 1 | 2012 | 34 | 0.090 |
Why?
|
| Models, Biological | 1 | 2017 | 1180 | 0.090 |
Why?
|
| Leukemia | 1 | 2012 | 62 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 3 | 2019 | 893 | 0.090 |
Why?
|
| Learning | 1 | 2013 | 176 | 0.090 |
Why?
|
| Osteoblasts | 2 | 2024 | 198 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2024 | 427 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2017 | 1508 | 0.080 |
Why?
|
| Mice, Transgenic | 2 | 2022 | 1271 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 618 | 0.070 |
Why?
|
| Diterpenes, Kaurane | 1 | 2006 | 2 | 0.070 |
Why?
|
| Diterpenes | 1 | 2006 | 21 | 0.070 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2006 | 83 | 0.060 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2006 | 58 | 0.060 |
Why?
|
| Apoptosis | 2 | 2012 | 1066 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2018 | 318 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 716 | 0.060 |
Why?
|
| Utrophin | 1 | 2024 | 4 | 0.060 |
Why?
|
| Mice, Inbred mdx | 1 | 2024 | 15 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2006 | 189 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2019 | 2154 | 0.050 |
Why?
|
| Dystrophin | 1 | 2024 | 31 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2024 | 96 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 81 | 0.050 |
Why?
|
| Mutation | 2 | 2022 | 2576 | 0.050 |
Why?
|
| Activins | 1 | 2023 | 54 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 293 | 0.050 |
Why?
|
| Terminal Repeat Sequences | 1 | 2022 | 13 | 0.050 |
Why?
|
| Codon, Terminator | 1 | 2022 | 23 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2024 | 219 | 0.050 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2022 | 27 | 0.050 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2022 | 37 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 3387 | 0.050 |
Why?
|
| Compassionate Use Trials | 1 | 2021 | 2 | 0.050 |
Why?
|
| Thymidine | 1 | 2021 | 25 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 661 | 0.050 |
Why?
|
| RNA, Transfer | 1 | 2022 | 88 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2021 | 82 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 422 | 0.040 |
Why?
|
| Swine | 1 | 2021 | 368 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 90 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2020 | 85 | 0.040 |
Why?
|
| Organ Culture Techniques | 1 | 2019 | 69 | 0.040 |
Why?
|
| Serogroup | 1 | 2019 | 35 | 0.040 |
Why?
|
| Cartilage | 1 | 2019 | 34 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 839 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 734 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 193 | 0.040 |
Why?
|
| Locomotion | 1 | 2019 | 116 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2019 | 115 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2020 | 201 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2019 | 303 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 287 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 288 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 352 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 1594 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2017 | 215 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2020 | 1143 | 0.030 |
Why?
|
| Smad7 Protein | 1 | 2015 | 1 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 794 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1110 | 0.030 |
Why?
|
| Adult | 2 | 2022 | 16634 | 0.030 |
Why?
|
| Extinction, Psychological | 1 | 2013 | 14 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2013 | 46 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2013 | 130 | 0.030 |
Why?
|
| Morphine | 1 | 2013 | 58 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2013 | 185 | 0.020 |
Why?
|
| Bortezomib | 1 | 2012 | 56 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 375 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 610 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 890 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 1553 | 0.020 |
Why?
|
| Female | 2 | 2024 | 32502 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 937 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 1978 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 533 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1601 | 0.020 |
Why?
|
| U937 Cells | 1 | 2006 | 10 | 0.020 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2006 | 11 | 0.020 |
Why?
|
| Cytarabine | 1 | 2006 | 35 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 82 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7723 | 0.020 |
Why?
|
| Plants, Medicinal | 1 | 2006 | 61 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2006 | 142 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 77 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2006 | 271 | 0.020 |
Why?
|
| Plant Extracts | 1 | 2006 | 172 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 14261 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 17371 | 0.010 |
Why?
|